Impact of patient reimbursement timing and patient out-of-pocket expenses on medication adherence in patients covered by private drug insurance plans

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 5, 2016, Pages 539-547

  Després, François ^a   Forget, Amélie ^b   Kettani, Fatima Zohra ^b   Blais, Lucie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADOLESCENT; ADULT; AGED; CANADA; DRUG COST; ECONOMICS; FACTUAL DATABASE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CANADA; DATABASES, FACTUAL; DRUG COSTS; DRUG PRESCRIPTIONS; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84969630214     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.5.539     Document Type: Article

References (33)

1. Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207.
2. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc (Wash). 2000;40(4):475-85.
3. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-42.
4. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
5. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-86.
6. Domino ME, Martin BC, Wiley-Exley E, et al. Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment. Health Serv Res. 2011;46(3):900-19.
7. Patterson ME, Blalock SJ, Smith AJ, Murray MD. Associations between prescription copayment levels and beta-blocker medication adherence in commercially insured heart failure patients 50 years and older. Clin Ther. 2011;33(5):608-16.
8. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care. 2010;16(1):e20-e34.
9. Yoon J, Ettner SL. Cost-sharing and adherence to antihypertensives for low and high adherers. Am J Manag Care. 2009;15(11):833-40.
10. Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med. 2008;23(8):1131-36.
11. Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med. 2008;50(5):535-41.
12. Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748-57.
13. Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy. 2006;26(8):1157-64.
14. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12(Spec no.):SP11-19.
15. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9):509-17.
16. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678-83.
17. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16(8):589-600.
18. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007;115(16):2128-35.
19. Régie de l'assurance maladie du Québec. Rapport annuel de gestion 2010-2011. 2011. Available at: http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/citoyens/fr/rapports/rappann1011-fr.pdf. Accessed February 13, 2016.
20. Assayag J, Forget A, Kettani FZ, Beauchesne MF, Moisan J, Blais L. The impact of the type of insurance plan on adherence and persistence with antidepressants: a matched cohort study. Can J Psychiatry. 2013;58(4):233-39.
21. Cyr MC, Beauchense MF, Lemiere C, Blais L. Comparison of the adherence and persistence to inhaled corticosteroids among adult patients with public and private drug insurance plans. J Popul Ther Clin Pharmacol. 2013;20(1):e26-41.
22. Despres F, Perreault S, Lalonde L, Forget A, Kettani FZ, Blais L. Impact of drug plans on adherence to and the cost of antihypertensive medications among patients covered by a universal drug insurance program. Can J Cardiol. 2014;30(5):560-67.
23. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280-88.
24. Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin. 2010;26(12):2877-87.
25. Austin PC. Bootstrap model selection had similar performance for selecting authentic and noise variables compared to backward variable elimination: a simulation study. J Clin Epidemiol. 2008;61(10):1009-17.
26. Kulik A, Desai NR, Shrank WH, et al. Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial. Circulation. 2013;128(11 Suppl 1):S219-25.
27. Viswanathan M, Golin CE, Jones CD, et al. Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness). Evid Rep Technol Assess (Full Rep). 2012;(208.4):1-685.
28. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157(11):785-95.
29. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-97.
30. Baicker K, Mullainathan S, Schwartzstein J. Behavioral hazard in health insurance*. Q J Econ. 2015;130(4):1623-67.
31. Alsabbagh MH, Lemstra M, Eurich D, et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health. 2014;17(2):288-96.
32. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-21.
33. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304-14.